| Literature DB >> 29643835 |
Ying-Zhi Liang1,2, Jing Dong3, Jie Zhang1,2, Shuo Wang1,2, Yan He1,2, Yu-Xiang Yan1,2.
Abstract
BACKGROUND: Chronic stress plays an important role in the development of type 2 diabetes mellitus (T2DM) and insulin resistance (IR). MicroRNAs (miRNAs) play key roles in mediating stress responses by regulating the expression of target genes. This study systematically screened and identified the neuroendocrine stress response-related circulating miRNAs which are associated with T2DM and IR.Entities:
Keywords: biomarker; insulin resistance; microRNA; neuroendocrine; stress; type 2 diabetes mellitus
Year: 2018 PMID: 29643835 PMCID: PMC5882838 DOI: 10.3389/fendo.2018.00132
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Demographic and clinical characteristics of participants in the microRNA profile study.
| Variable | Type 2 diabetes mellitus ( | Control ( | |
|---|---|---|---|
| Age (years) | 49.10 ± 3.84 | 49.00 ± 3.97 | 0.955 |
| Gender (male/female) | 5/5 | 5/5 | 1.000 |
| BMI (kg/m2) | 26.84 ± 2.85 | 22.74 ± 1.91 | 0.001 |
| WC (cm) | 89.74 ± 11.78 | 78.80 ± 6.66 | 0.020 |
| SBP (mmHg) | 125.50 ± 12.98 | 114.20 ± 18.04 | 0.125 |
| DBP (mmHg) | 79.30 ± 7.07 | 73.00 ± 6.72 | 0.056 |
| TC (mmol/l) | 5.49 ± 1.14 | 4.87 ± 0.83 | 0.184 |
| TG (mmol/l) | 2.28 ± 2.12 | 1.02 ± 0.39 | 0.094 |
| LDLC (mmol/l) | 2.79 ± 0.84 | 2.35 ± 0.43 | 0.166 |
| HDLC (mmol/l) | 1.38 ± 0.43 | 1.83 ± 0.40 | 0.028 |
| FPG (mmol/l) | 11.91 ± 1.83 | 4.93 ± 0.40 | <0.001 |
| HbA1c (%) | 8.66 ± 0.87 | 4.97 ± 0.24 | <0.001 |
| Insulin (uIU/ml) | 16.50 ± 3.49 | 10.58 ± 1.52 | <0.001 |
| HOMA-IR | 8.64 ± 2.32 | 2.32 ± 0.43 | <0.001 |
| Smoking ( | 0 | 0 | – |
| Alcohol use ( | 0 | 1 | 0.500 |
| Physical activity ( | 7 | 5 | 0.650 |
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; FPG, fast plasma glucose; HOMA-IR, homeostasis model assessment of insulin.
*Fisher exact P value.
Figure 1Differentially expressed plasma microRNAs (miRNAs) between type 2 diabetes mellitus (T2DM) patients (n = 10) and healthy controls (n = 10) in microarray. Each row represents one miRNA, and each column represents a plasma sample. The legend on the right indicates the miRNA represented in the corresponding row. The relative miRNA expression is depicted according to the color scale. Red indicates upregulation; green indicates downregulation. The numbers with case indicate newly diagnosed T2DM patients; numbers with control indicate healthy controls.
Differential microRNAs (miRNA) expression in type 2 diabetes mellitus (T2DM) vs. control group.
| miRNA | Mean intensities in T2DM | Mean intensities in controls | Fold change | Up/Down | (Predicted) target gene | Prediction programs | |
|---|---|---|---|---|---|---|---|
| let-7b-5p | 1,305 | 397 | 2.79E-07 | 3.28 | Up | ADRB2/ADRB3 ( | a,b |
| let-7i-5p | 461 | 173 | 2.41E-09 | 2.66 | Up | ADRB2/ADRB3 | a,b |
| miR-142-3p | 503 | 1,040 | 5.47E-06 | 0.48 | Down | Corticotropin-releasing hormone (CRH)/interleukin-6 ( | a,b,c |
| miR-144-3p | 219 | 107 | 6.68E-11 | 2.05 | Up | NR3C1 ( | a,c |
| miR-155-5p | 204 | 100 | 4.56E-09 | 2.04 | Up | NR3C1/CYP11B1 | a,b,c |
| miR-29a-5p | 208 | 98 | 7.73E-09 | 2.12 | Up | NR3C1/CRHR1 | a,b |
a, miRecords; b, TarBase; c, miRTarBase.
Demographic and clinical characteristics of study participants in the validation study.
| Variable | Type 2 diabetes mellitus ( | Impaired fasting glucose (IFG) ( | Control ( | |
|---|---|---|---|---|
| Age (years) | 54.75 ± 7.53 | 52.53 ± 7.51 | 52.84 ± 8.85 | 0.111 |
| Gender (male/female) | 69/43 | 38/34 | 53/41 | 0.478 |
| BMI (kg/m2) | 27.11 ± 3.17 | 26.26 ± 2.97 | 23.86 ± 3.27 | <0.001 |
| WC(cm) | 92.12 ± 8.46a,b | 88.93 ± 9.18 | 82.05 ± 9.57 | <0.001 |
| SBP (mmHg) | 138.82 ± 21.19 | 133.98 ± 17.57 | 123.90 ± 17.85 | <0.001 |
| DBP (mmHg) | 86.30 ± 12.64a,b | 82.39 ± 10.53 | 77.98 ± 12.33 | <0.001 |
| TC(mmol/l) | 5.49 ± 1.15a,b | 5.07 ± 0.93 | 4.91 ± 0.94 | <0.001 |
| TG(mmol/l) | 2.98 ± 2.86a,b | 1.88 ± 1.04 | 1.71 ± 1.43 | <0.001 |
| LDLC (mmol/l) | 3.26 ± 1.25a,b | 2.81 ± 0.81 | 2.40 ± 0.82 | <0.001 |
| HDLC (mmol/l) | 1.21 ± 0.57 | 1.29 ± 0.34 | 1.41 ± 0.39 | 0.008 |
| FPG (mmol/l) | 9.48 ± 2.62a,b | 6.44 ± 0.24 | 4.94 ± 0.38 | <0.001 |
| HbA1c (%) | 7.58 ± 1.54a,b | 5.74 ± 0.60 | 5.16 ± 0.39 | <0.001 |
| Insulin (uIU/ml) | 14.88 ± 2.95a,b | 13.05 ± 2.67 | 9.27 ± 2.55 | <0.001 |
| HOMA-IR | 6.31 ± 2.19a,b | 3.74 ± 0.82 | 2.04 ± 0.59 | <0.001 |
| Smoking ( | 16, 17.02 | 11, 15.28 | 17, 15.18 | 0.750 |
| Alcohol use ( | 12, 10.71 | 9, 12.50 | 5, 5.32 | 0.236 |
| Physical activity ( | 71, 63.39 | 47, 65.28 | 69, 73.40 | 0.286 |
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; FPG, fast plasma glucose; HOMA-IR, homeostasis model assessment of insulin.
*χ.
.
.
MicroRNA and stress hormonal characteristics in the three compared groups.
| Variable | Type 2 diabetes mellitus ( | Impaired fasting glucose (IFG) ( | Control ( | |
|---|---|---|---|---|
| let-7b | 11.00 ± 4.23a,b | 8.98 ± 3.44 | 6.52 ± 3.15 | <0.001 |
| let-7i | 7.08 ± 4.07 | 6.82 ± 4.19 | 6.48 ± 4.39 | 0.314 |
| miR-142 | 9.25 ± 4.34 | 10.48 ± 4.44 | 13.61 ± 4.35 | <0.001 |
| miR-144 | 53.82 ± 9.54a,b | 50.98 ± 8.02 | 45.20 ± 9.51 | <0.001 |
| miR-155 | 0.59 ± 0.73 | 0.61 ± 0.67 | 0.63 ± 0.80 | 0.940 |
| miR-29a | 7.42 ± 4.95 | 7.35 ± 4.55 | 5.58 ± 4.31 | 0.001 |
| E (pg/ml) | 153.34 ± 49.91 | 139.09 ± 48.60 | 135.80 ± 52.98 | 0.032 |
| NE (pg/ml) | 413.00 ± 94.57 | 392.20 ± 88.04 | 379.40 ± 102.26 | 0.041 |
| Cortisol (ng/ml) | 219.62 ± 36.59a,b | 204.50 ± 35.22 | 176.49 ± 34.74 | <0.001 |
| CRH (ng/ml) | 5.40 ± 0.61 | 5.39 ± 0.55 | 5.04 ± 0.47 | <0.001 |
| IL-6 (pg/ml) | 134.07 ± 16.62a,b | 126.58 ± 19.26 | 122.50 ± 21.51 | <0.001 |
E, adrenaline; NE, norepinephrine; CRH, corticotropin-releasing hormone; IL-6, interleukin-6.
*Skewed distributed and analyzed by log-transformed values.
.
.
Figure 2Comparison of plasma microRNAs expression based on quantitative real-time polymerase chain reaction readings among type 2 diabetes mellitus, impaired fasting glucose, and control groups. Data are represented by scatter diagram. *P < 0.05, **P < 0.01, ns, not significant.
Spearman correlation among the microRNAs and stress hormones and HOMA-IR.
| E | NE | Cortisol | CRH | IL-6 | HOMA-IR | |
|---|---|---|---|---|---|---|
| let-7b | 0.213 | 0.216 | 0.324 | 0.257 | 0.164 | 0.469 |
| miR-142 | −0.086 | −0.102 | −0.241 | −0.304 | −0.225 | −0.436 |
| miR-144 | 0.063 | 0.086 | 0.343 | 0.198 | 0.139 | 0.419 |
| miR-29a | −0.029 | −0.025 | 0.183 | 0.120 | 0.123 | 0.196 |
| let-7b | 0.213 | 0.191 | 0.105 | 0.207 | 0.095 | 0.214 |
| miR-142 | −0.053 | −0.069 | −0.068 | −0.200 | −0.221 | −0.223 |
| miR-144 | −0.023 | −0.017 | 0.226 | 0.174 | 0.025 | 0.202 |
| miR-29a | −0.114 | −0.123 | 0.062 | −0.003 | 0.110 | 0.149 |
| let-7b | 0.187 | 0.180 | 0.011 | 0.092 | 0.028 | 0.165 |
| miR-142 | −0.046 | −0.042 | −0.110 | −0.173 | −0.177 | −0.184 |
| miR-144 | 0.147 | 0.166 | 0.192 | −0.013 | 0.046 | 0.192 |
| miR-29a | −0.077 | −0.078 | 0.117 | 0.033 | 0.120 | 0.045 |
| let-7b | 0.092 | 0.101 | 0.179 | 0.129 | 0.082 | 0.030 |
| miR-142 | 0.026 | 0.001 | 0.095 | −0.157 | −0.079 | −0.014 |
| miR-144 | −0.077 | −0.037 | 0.145 | 0.077 | 0.045 | 0.092 |
| miR-29a | 0.037 | 0.033 | 0.119 | 0.115 | 0.022 | 0.019 |
E, adrenaline; NE, norepinephrine; CRH, corticotropin-releasing hormone; IL-6, interleukin-6; HOMA-IR, homeostasis model assessment of insulin.
*P < 0.0125.
Univariate and multiple logistic regression analysis for the risk of type 2 diabetes mellitus (T2DM) and impaired fasting glucose (IFG).
| Models | T2DM | IFG | ||
|---|---|---|---|---|
| OR (95% CI) | OR* (95% CI) | |||
| Univariate model | 1.36 (1.24, 1.49) | <0.001 | 1.25 (1.23, 1.38) | <0.001 |
| Multivariate model 1 | 1.36 (1.23, 1.49) | <0.001 | 1.22 (1.10, 1.35) | <0.001 |
| Multivariate model 2 | 1.35 (1.22, 1.50) | <0.001 | 1.23 (1.10, 1.37) | <0.001 |
| Multivariate model 3 | 1.33 (1.10, 1.50) | <0.001 | 1.20 (1.07, 1.35) | 0.002 |
| Univariate model | 0.80 (0.74, 0.86) | <0.001 | 0.85 (0.78, 0.92) | <0.001 |
| Multivariate model 1 | 0.78 (0.73, 0.85) | <0.001 | 0.84 (0.77, 0.92) | <0.001 |
| Multivariate model 2 | 0.80 (0.74, 0.88) | <0.001 | 0.86 (0.79, 0.95) | 0.001 |
| Multivariate model 3 | 0.83 (0.75, 0.93) | <0.001 | 0.86 (0.78, 0.94) | 0.002 |
| Univariate model | 1.10 (1.06, 1.14) | <0.001 | 1.08 (1.04, 1.12) | <0.001 |
| Multivariate model 1 | 1.10 (1.06, 1.14) | <0.001 | 1.12 (1.07, 1.18) | <0.001 |
| Multivariate model 2 | 1.09 (1.05, 1.13) | <0.001 | 1.11 (1.05, 1.17) | <0.001 |
| Multivariate model 3 | 1.08 (1.03, 1.13) | 0.004 | 1.12 (1.05, 1.18) | <0.001 |
| Univariate model | 1.09 (1.03, 1.16) | 0.007 | 1.09 (1.02, 1.18) | 0.014 |
| Multivariate model 1 | 1.09 (1.02, 1.14) | 0.010 | 1.09 (1.01, 1.17) | 0.025 |
| Multivariate model 2 | 1.08 (1.01, 1.16) | 0.027 | 1.09 (1.01, 1.18) | 0.027 |
| Multivariate model 3 | 1.10 (1.00, 1.20) | 0.036 | 1.10 (1.01, 1.20) | 0.033 |
.
.
.
OR, odds ratio; CI, confidence interval.
Stepwise multiple linear regression analysis of the relationship between miRNA and homeostasis model assessment of insulin resistance.
| Variables | Adjusted for BMI | Adjusted for WC | ||
|---|---|---|---|---|
| β coefficient | β coefficient | |||
| BMI/WC | 0.106 | 0.004 | 0.034 | 0.009 |
| Triglycerides (TG) | 0.146 | 0.029 | 0.141 | 0.035 |
| let-7b | 0.142 | <0.001 | 0.144 | <0.001 |
| miR-142 | −0.068 | 0.010 | −0.068 | 0.010 |
| miR-144 | 0.045 | <0.001 | 0.045 | <0.001 |
| miR-29a | 0.049 | 0.043 | 0.049 | 0.047 |
Variables entered in step 1: age, gender, smoking, drinking, physical activity, TCH, TG, HDLC, LDLC, SBP, DBP, WC/BMI, let-7b, miR-142, miR-144, and miR-29a.
WC, waist circumference; BMI, body mass index; HDLC, high-density lipoprotein cholesterol.
Figure 3Receiver operating characteristic curve analysis for type 2 diabetes mellitus prediction. Area under the curve (AUC) estimation for the microRNAs: (A) let-7b, (B) miR-142, (C) miR-144, and (D) miR-29a.
Figure 4Receiver operating characteristic plot for the miRNA panel (let-7b, miR-142, and miR-144) discriminating type 2 diabetes mellitus.